Patient-derived xenografts (PDX) are models of cancer where the tissue or cells from a patient’s tumour are implanted into an immune deficient or humanised mouse. These models are used to create an environment that allows for the natural growth of cancer, monitoring and corresponding treatment evaluations for the original patient. Global patient-derived xenograft models market value is projected to be $77.4 Billion in 2017 and is expected to generate revenue of around $228.15 Billion by the end of 2024, growing at a CAGR of around 16.7% between 2017 and 2024. Continuous support for cancer research from the public as well as private sector and growing demand for personalised medicine are the factors enhancing the growth of the market. Stringent guidelines for the use of animal models in cancer research and limitations of PDX models systems are the factors which hamper the market growth. Rising demand for humanised PDX models and emerging economies is becoming opportunities for patient-derived xenograft models market.
Research Study Objectives:
- Define, estimate, and forecast the Patient-Derived Xenograft Models market statistics by type, tumour type, application, end user and regions concerning the individual growth drivers, market trends and their contribution toward the Patient-Derived Xenograft Models market growth
- Provides comprehensive information regarding the key factors influencing the market growth (Drivers, Restraints & Challenges, and Opportunities)
- Estimate & forecast the market size of all the segments concerning geographies including North America, Europe, Asia Pacific (APAC), South America and the Middle East and Africa (MEA).
- Recent competitive developments including M&A (Mergers and Acquisitions), Partnerships, and Product Innovations are provided in the Patient-Derived Xenograft Models Market Analysis
- Analysis and conclusions on the future Patient-Derived Xenograft Models market outlook.
Top-down and bottom-up approaches are used to validate the Patient-Derived Xenograft Models Market Size and are used to estimate the size of
other dependent submarkets. Key players in the market are identified through various secondary sources; databases including Bloomberg Businessweek, Hoovers, Factiva, journals and associations and the market revenues are estimated and are thoroughly validated through primary and secondary research. Secondary research involves the study of annual and financial reports of top players in the market, whereas primary research includes extensive interviews with the KoL’s such as CEOs, directors, board members, VP’s, sales managers, engineers, marketing executives, technicians, account managers, investors, strategic decision makers and others. The Patient-Derived Xenograft Models Market shares and breakdowns are determined using secondary sources and are verified by the primary sources. All possible parameters/factors that are affecting the Patient-Derived Xenograft Models market demand are covered in the research study are verified through primary research, analysed and interpreted to get the final qualitative and quantitative data. This data is collected and added with detailed analysis from Envision Inteligence and presented in this report.
The scope of the Report
The Patient-Derived Xenograft Models market segmentation is as follows:
By Type
By Tumour Type
- Gastrointestinal tumour models
- Gynaecological tumour models
- Respiratory tumour models
- Urological tumour models
- Haematological tumour models
- Other tumour models
By Application
- Preclinical drug development and basic cancer research
- Biomarker analysis
By End User
- Pharmaceutical &biotechnology companies
- Contract research organisations
- Academic &research institutions
Geographical Analysis:
Patient-derived xenograft models Market is segmented by geography into North America, South America, Europe, APAC and Middle East & Africa. U.S., Canada, Mexico and Costa Rica are analysed under North American region which is usually turning as the hotspot in the market. The South American region is further segregated into Brazil, Argentina, Chile, Columbia and some other emerging economies. In Europe, the market is extensively examined by covering U.K., Germany, France, Italy, Spain, Netherlands, Poland, Switzerland and some other promising economies. APAC is further categorised by countries into China, India,
Japan, South Korea, Australia & New Zealand, Malaysia, Singapore and many other emerging nations. In the Middle East & African region, Saudi Arabia, UAE, Iran, Iraq, Qatar, South Africa, Algeria, Morocco, Nigeria and so on countries are evaluated to understand the market growth lucidly.
Customization Options:
With the given research report, Envision Inteligence offers customisations as per the client’s specific requirements. The following customisation options offered for the Patient-Derived Xenograft Models Market include:
- Scope Revision
- Geographic Analysis
- Company Profiles
- Historical Data & Forecasting
- Key Contact Persons in companies
Global Patient-Derived Xenograft Models Market Research Report Includes:
- An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
- To have a complete market analysis through industry value chain analysis, Porter’s Five Force Model, PESTLE, SWOTanalysis, and Y-o-Y analysis.
- Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
- Identifying DROC in the current market and their impact on altering market dynamics.
- Competitive landscape analysis to identify the merger and acquisition which will have a comparative financial study with significant competitors.
- Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
- Identify the latest developments, market shares and strategies that are employed by the significant Patient-Derived Xenograft Models market players, such as
- Champions Oncology Inc.
- Charles River Laboratories International Inc
- Crown Bioscience Inc.
- Hera Biolabs.
- Horizon Discovery Group Plc.
- Along with these companies, many other companies are considered in the report while analysing the Global Patient-Derived Xenograft Models competitive strategies and environment. These companies held substantial share-owning to the nature of the industry whereas, the rest of the market shares are marginal chunks to regional and local level manufacturers. Other players also have considerable presence owing to its robust brand image, geographical reach and stable customer base.
